Paul Ronald Bell
Direttore/Membro del Consiglio presso BIOTA HOLDINGS LTD.
Posizioni attive di Paul Ronald Bell
Società | Posizione | Inizio | Fine |
---|---|---|---|
BIOTA HOLDINGS LTD. | Direttore/Membro del Consiglio | 28/07/2009 | - |
Independent Dir/Board Member | 08/09/2006 | - | |
Westmead Millennium Institute for Medical Research | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Paul Ronald Bell
Precedenti posizioni note di Paul Ronald Bell
Società | Posizione | Inizio | Fine |
---|---|---|---|
COCHLEAR LIMITED | Direttore/Membro del Consiglio | 08/07/2009 | 14/10/2014 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Direttore/Membro del Consiglio | 09/11/2012 | 01/05/2013 |
MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2002 | 01/01/2002 |
Novozymes Biopharma AU Ltd.
Novozymes Biopharma AU Ltd. Pharmaceuticals: MajorHealth Technology Novozymes Biopharma AU Ltd. manufactures pharmaceuticals. The company is headquartered in Thebarton, Australia. | Direttore/Membro del Consiglio | 11/02/2011 | - |
Bio-Link Partners Ltd.
Bio-Link Partners Ltd. Miscellaneous Commercial ServicesCommercial Services Bio-Link Partners Ltd. operates as a biotechnology business development company. The company is headquartered in Eveleigh, Australia. | Direttore/Membro del Consiglio | 11/02/2011 | - |
The Garvan Institute of Medical Research
The Garvan Institute of Medical Research Miscellaneous Commercial ServicesCommercial Services The Garvan Institute of Medical Research engages in the provision of biomedical research. It focuses in cancer, genomics and epigenetics, immunity and inflammation, healthy ageing, clinical trials, and research centres. The company was founded in 1963 and is headquartered in Darlinghurst, Australia. | Corporate Officer/Principal | 09/02/2011 | - |
Merck Sharp & Dohme (Australia) Pty Ltd.
Merck Sharp & Dohme (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme (Australia) Pty Ltd. is an Australian research-intensive biopharmaceutical company committed to saving and improving lives. The company is based in North Ryde, Australia and is dedicated to following the science to tackle some of the world's greatest health threats. MSD Australia has a long legacy of research in infectious disease and has been mobilizing its scientific expertise and experience to develop an effective response to the COVID-19 pandemic since it was first recognized. | Corporate Officer/Principal | - | 14/02/2011 |
Presidente | 14/02/2011 | - |
Formazione di Paul Ronald Bell
University of Canterbury | Graduate Degree |
Statistiche
Distribuzione geografica
Australia | 8 |
Stati Uniti | 3 |
Nuova-Zelanda | 2 |
Posizioni
Director/Board Member | 6 |
Corporate Officer/Principal | 3 |
Independent Dir/Board Member | 1 |
Settori
Health Technology | 7 |
Commercial Services | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
COCHLEAR LIMITED | Health Technology |
Aziende private | 7 |
---|---|
Biota Holdings Pty Ltd.
Biota Holdings Pty Ltd. Pharmaceuticals: MajorHealth Technology Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia. | Health Technology |
Novozymes Biopharma AU Ltd.
Novozymes Biopharma AU Ltd. Pharmaceuticals: MajorHealth Technology Novozymes Biopharma AU Ltd. manufactures pharmaceuticals. The company is headquartered in Thebarton, Australia. | Health Technology |
The Garvan Institute of Medical Research
The Garvan Institute of Medical Research Miscellaneous Commercial ServicesCommercial Services The Garvan Institute of Medical Research engages in the provision of biomedical research. It focuses in cancer, genomics and epigenetics, immunity and inflammation, healthy ageing, clinical trials, and research centres. The company was founded in 1963 and is headquartered in Darlinghurst, Australia. | Commercial Services |
Merck Sharp & Dohme (Australia) Pty Ltd.
Merck Sharp & Dohme (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme (Australia) Pty Ltd. is an Australian research-intensive biopharmaceutical company committed to saving and improving lives. The company is based in North Ryde, Australia and is dedicated to following the science to tackle some of the world's greatest health threats. MSD Australia has a long legacy of research in infectious disease and has been mobilizing its scientific expertise and experience to develop an effective response to the COVID-19 pandemic since it was first recognized. | Health Technology |
Bio-Link Partners Ltd.
Bio-Link Partners Ltd. Miscellaneous Commercial ServicesCommercial Services Bio-Link Partners Ltd. operates as a biotechnology business development company. The company is headquartered in Eveleigh, Australia. | Commercial Services |
Westmead Millennium Institute for Medical Research | |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
- Borsa valori
- Insiders
- Paul Ronald Bell
- Esperienza